Direct Answer
Cash runway is an estimate of how many months or quarters a biotech company can continue operating at its current spending rate before it runs out of cash. It's calculated by dividing current cash and investments by the company's quarterly (or monthly) cash burn rate. Because most pre-revenue or early-revenue biotech companies fund operations entirely from their existing cash balance rather than from product sales, runway is one of the first numbers investors and analysts check when assessing a clinical-stage company's financial health.
Key Takeaways
- Runway = cash and investments ÷ burn rate. The calculation divides a company's current cash and investment balance by how much cash it uses per quarter or month, producing an estimate of how many periods that cash will last.
- It matters most for pre-revenue and early-revenue biotechs. Companies still in clinical development typically have little or no product revenue offsetting research, trial, and operating costs, so the existing cash balance is often the primary funding source.
- Running low on cash carries real consequences. A biotech that lets its runway shrink too far can be forced into a dilutive capital raise, a pipeline-rights partnership struck from a weaker negotiating position, or, in severe cases, a wind-down of operations.
- It's an estimate, not a guarantee. Runway assumes spending continues at roughly its recent pace; a company that accelerates a trial, adds headcount, or cuts a program will burn cash faster or slower than the estimate implies.
- The inputs come straight from SEC filings. Cash and investments and cash used in operations are both reported on the balance sheet and cash flow statement inside a company's 10-K and 10-Q filings.
How Cash Runway Is Calculated
The two inputs
Cash runway needs exactly two numbers. The first is current cash and investments, the total of cash, cash equivalents, and short-term investments a company reports on its balance sheet at a given point in time. The second is the cash burn rate, the amount of cash the company uses in its operations over a recent period, typically expressed per quarter or per month. Both figures come directly from a company's financial statements, most reliably its 10-K (annual) or 10-Q (quarterly) filings on file with the SEC.
The formula
Cash runway (in quarters) = current cash and investments ÷ quarterly cash burn rate. To express the result in months, either use a monthly burn rate in the denominator, or take the quarters figure and multiply by three. The mechanics are simple; the judgment is in choosing which burn-rate figure to use and how much confidence to place in the assumption that spending continues at that pace.
Why this metric exists
Cash runway is a critical metric for pre-revenue or early-revenue biotech companies because, without meaningful product sales, the cash balance is what stands between the company and the need for outside financing. Running low on cash can force a company to raise capital on dilutive terms, issuing new shares at a price or on terms less favorable to existing shareholders than it could command with a longer runway, to partner away rights to part of its drug pipeline in exchange for upfront cash from a larger partner, or, in severe cases, to wind down operations entirely. A company negotiating a financing or partnership deal with 18 months of runway left is generally in a stronger position than one negotiating with three months left.
Burn rate isn't always steady
Because runway is a projection built from a recent burn rate, it's sensitive to changes in spending. A company entering a pivotal Phase 3 trial, expanding manufacturing ahead of a potential approval, or adding commercial infrastructure will typically see its burn rate rise, shortening runway even if the cash balance hasn't changed. Conversely, a company that halts a program or reduces headcount can extend its runway without raising additional capital. This is why runway is best treated as a point-in-time estimate that needs to be revisited each time a company reports updated financials, not a fixed countdown.
Worked Example
Hypothetical example, for education only. The figures below are illustrative and do not describe any real company.
- Start with the cash balance: A clinical-stage biotech reports $180 million in cash, cash equivalents, and short-term investments on its most recent balance sheet.
- Find the burn rate: Its cash flow statement shows $30 million in net cash used in operating activities for the most recent quarter.
- Divide: $180 million ÷ $30 million per quarter = 6 quarters of runway.
- Convert to months: 6 quarters × 3 months = 18 months of estimated runway from the date of that balance sheet.
- Put it in context: If the company's next major catalyst, say, a Phase 3 data readout, is expected in 14 months, its 18-month runway covers that event with some cushion. If the readout were expected in 22 months instead, the same 18-month runway would leave the company needing to raise capital, or announce a partnership, before it reaches that catalyst.
Limitations and Common Mistakes
Treating burn rate as fixed
The most common error is projecting runway forward using a single quarter's burn rate without asking whether spending is likely to change. A company ramping up toward a pivotal trial or a commercial launch will typically burn cash faster than its trailing quarterly average suggests, which means a runway estimate built on last quarter's numbers alone can overstate how much time the company actually has.
Ignoring the timing of known catalysts and obligations
A runway figure by itself doesn't say whether it's enough. Eighteen months of runway is very different information depending on whether a key trial readout, regulatory decision, or debt maturity falls inside or outside that window. Runway is most useful when compared against a company's own disclosed timeline of upcoming events, not read as a standalone number.
Mixing up gross cash burn and net cash burn
Some companies have modest product or licensing revenue, milestone payments, or interest income alongside their operating spending. Using total operating expenses as the burn rate, rather than net cash actually used in operations (which already nets out any incoming cash), can understate runway. The cash flow statement's operating activities section is the more reliable source than the income statement for this reason.
Relying only on a company's self-reported runway estimate
Many biotech companies state their own estimated runway in earnings releases or filings, which is a useful data point but reflects management's own assumptions about future spending, assumptions that can change. Checking the underlying cash and burn-rate figures in the financial statements, rather than taking a headline runway figure at face value, gives a clearer and more independently verifiable picture.
Forgetting that runway is a range, not a precise date
Because it's built from an average recent burn rate and a snapshot cash balance, cash runway is inherently an estimate, not a scheduled event. Real spending fluctuates quarter to quarter, so treating a runway estimate as a precise "out of cash" date rather than a general planning horizon overstates the precision the underlying numbers actually support.
FAQ
What is biotech cash runway?
Cash runway is an estimate of how many months or quarters a biotech company can continue operating at its current spending rate before it runs out of cash. It is calculated by dividing current cash and investments by the company's quarterly (or monthly) cash burn rate. Runway is a critical metric for pre-revenue or early-revenue biotech companies, since running low on cash can force a company to raise capital on dilutive terms, partner away rights to its pipeline, or in severe cases wind down operations.
How do you calculate a biotech company's cash runway?
Divide current cash and investments (cash, cash equivalents, and short-term investments as reported on the balance sheet) by the recent cash burn rate (the average cash used in operations per quarter or per month). Cash and investments ÷ quarterly burn rate gives runway in quarters; multiply by three to convert to months. Both inputs come from a company's 10-K or 10-Q filings, and the calculation only holds if spending continues at roughly the same pace assumed in the estimate.
Is cash runway the same thing as burn rate?
No. Burn rate is the amount of cash a company consumes per period, typically measured as net cash used in operating activities per quarter or month. Cash runway is a derived figure that uses burn rate as an input: it divides the cash balance by the burn rate to estimate how long that cash will last. Burn rate answers "how fast is cash going out," while runway answers "how much time is left."
What happens when a biotech company's cash runway gets short?
A shrinking runway pressures a biotech company toward one of several outcomes: raising additional capital, often on dilutive terms if negotiated from a position of weakness (a lower share price or investor-favorable terms that reduce existing shareholders' ownership); partnering away rights to part of its drug pipeline in exchange for upfront cash; cutting spending by slowing or halting programs; or, in severe cases, winding down operations entirely. Which path a company takes typically depends on its pipeline stage, trial data, and the state of capital markets at the time.
Why does cash runway matter more for biotech than for most other sectors?
Many biotech companies, particularly clinical-stage ones, generate little or no product revenue for years while spending heavily on research and development and clinical trials. Without incoming revenue to offset spending, cash on the balance sheet is often the only thing standing between a company and a forced financing or wind-down. This makes runway a central financial-health metric for biotech investors in a way it typically isn't for a profitable, cash-generating business in another sector.
Where can investors find the inputs needed to calculate cash runway?
A company's cash and investments balance and its cash used in operating activities are both reported in its SEC filings, the balance sheet and cash flow statement inside the quarterly 10-Q and annual 10-K, available free through SEC EDGAR. Many biotech companies also state their own estimated cash runway directly in earnings releases and 10-Q/10-K filings, though the methodology behind a company's self-reported estimate should still be checked against the underlying financial statements.
What is a going concern statement and how does it relate to cash runway?
Auditors are required to evaluate whether a company can meet its obligations for a defined period ahead, and to flag substantial doubt where it cannot. For a clinical-stage biotech with less than that period of cash, the result is a going concern paragraph in the audited financial statements. It is not a prediction of failure, and companies frequently resolve it by raising capital afterwards. It is a formal signal that the runway has fallen inside the auditor assessment window, which usually sharpens the terms available in any subsequent financing.
How does an at-the-market equity program change a runway estimate?
An at-the-market facility lets a company sell registered shares into the open market gradually rather than through a single announced offering. Because the draws are incremental and disclosed after the fact, cash can arrive between reporting dates without a headline financing event. A runway calculated from the last reported balance can therefore understate the position. Checking whether such a program exists and how much capacity remains is part of reading the cash figure, though drawing on it dilutes existing holders as it goes.
How can a partnership or milestone payment extend runway without a financing?
Collaboration agreements often pay an upfront amount plus contingent payments tied to development or regulatory events, and may also cover a share of trial costs. Those inflows extend runway without issuing shares, which is why partnering is sometimes described as non-dilutive funding. The tradeoff is giving up economics on the asset, typically through shared rights or reduced future royalties. Because contingent payments depend on events that may not occur, they should be treated as possible rather than scheduled cash when estimating runway.
References
Disclaimer
This article is for educational and informational purposes only and does not constitute personalized investment, financial, or legal advice. Cash runway is an estimate based on recent spending patterns and can change materially as a company's operations evolve. Always verify current financial data from primary sources before making investment decisions. Trading involves risk, including the possible loss of principal.